share_log

Guangdong Taienkang Pharmaceutical Co., Ltd.'s (SZSE:301263) Last Week's 6.3% Decline Must Have Disappointed Retail Investors Who Have a Significant Stake

Guangdong Taienkang Pharmaceutical Co., Ltd.'s (SZSE:301263) Last Week's 6.3% Decline Must Have Disappointed Retail Investors Who Have a Significant Stake

广东泰恩康药品有限公司 (SZSE:301263) 上周6.3%的下跌一定让持有重要股份的散户投资者感到失望。
Simply Wall St ·  01/06 11:42

Key Insights

关键洞察

  • Guangdong Taienkang Pharmaceutical's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public
  • A total of 11 investors have a majority stake in the company with 50% ownership
  • 42% of Guangdong Taienkang Pharmaceutical is held by insiders
  • 广东泰恩康药品的重大零售投资者持股比例表明,关键决策受到大股东的影响。
  • 共有11位投资者在公司拥有大多数权益,持股比例为50%
  • 42%的广东泰恩康药品由内部人士持有。

A look at the shareholders of Guangdong Taienkang Pharmaceutical Co., Ltd. (SZSE:301263) can tell us which group is most powerful. And the group that holds the biggest piece of the pie are retail investors with 45% ownership. Put another way, the group faces the maximum upside potential (or downside risk).

查看广东泰恩康药品有限公司(深交所:301263)的股东,可以告诉我们哪个群体最强大。最大的一部分股权由持有45%股份的零售投资者掌握。换句话说,这个群体面临着最大的上行潜力(或下行风险)。

While insiders who own 42% came under pressure after market cap dropped to CN¥6.1b last week,retail investors took the most losses.

由于内部人士持有42%,在市值上周降至61亿人民币后承受了压力,散户投资者损失最大。

In the chart below, we zoom in on the different ownership groups of Guangdong Taienkang Pharmaceutical.

在下面的图表中,我们详细分析了广东太恩康药品的不同持股群体。

big
SZSE:301263 Ownership Breakdown January 6th 2025
深交所:301263 持股结构 2025年1月6日

What Does The Institutional Ownership Tell Us About Guangdong Taienkang Pharmaceutical?

机构持股对广东太恩康药品有什么启示?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

机构投资者通常将自己的回报与一个常见的指数回报进行比较。因此,他们通常会考虑购买纳入相关基准指数的大型公司股票。

As you can see, institutional investors have a fair amount of stake in Guangdong Taienkang Pharmaceutical. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Guangdong Taienkang Pharmaceutical's historic earnings and revenue below, but keep in mind there's always more to the story.

如您所见,机构投资者在广东太恩康药品中拥有相当数量的股份。这意味着为这些机构工作的分析师已经关注了这只股票,并对其表示认可。但就像其他任何人一样,他们也可能会犯错误。当多家机构拥有同一只股票时,总会存在‘拥挤交易’的风险。当此类交易出现问题时,多方可能会竞相快速抛售股票。在一家没有增长历史的公司中,这种风险更高。您可以在下面查看广东太恩康药品的历史收益和营业收入,但请记住,事情常常不止于此。

big
SZSE:301263 Earnings and Revenue Growth January 6th 2025
深交所:301263 2025年1月6日的营业收入和增长

Hedge funds don't have many shares in Guangdong Taienkang Pharmaceutical. With a 21% stake, CEO Hanjie Zheng is the largest shareholder. For context, the second largest shareholder holds about 16% of the shares outstanding, followed by an ownership of 3.7% by the third-largest shareholder.

对冲基金在广东太恩康药品的股份不多。拥有21%股份的首席执行官郑汉杰是最大的股东。为了更好地了解,第二大股东持有约16%的流通股份,而第三大股东则拥有3.7%的股份。

Looking at the shareholder registry, we can see that 50% of the ownership is controlled by the top 11 shareholders, meaning that no single shareholder has a majority interest in the ownership.

从股东登记册来看,我们可以看到前11大股东控制了50%的持有权,这意味着没有单一股东拥有多数持股。

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There is a little analyst coverage of the stock, but not much. So there is room for it to gain more coverage.

虽然研究公司机构持股可以为您的研究增值,但也建议研究分析师的建议,以更深入了解股票的预期表现。该股票的分析师覆盖较少,但也不是很多。因此,它有机会获得更多的覆盖。

Insider Ownership Of Guangdong Taienkang Pharmaceutical

广东太恩康药品的内部持股

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

内部人的定义在不同国家之间可能略有不同,但董事会成员始终被算作内部人。管理层最终向董事会负责。然而,管理者成为执行董事会成员并不罕见,特别是当他们是创始人或首席执行官时。

I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.

我通常认为内部人拥有股份是一件好事。然而,在某些情况下,这使得其他股东更难让董事会对决策负责。

Our information suggests that insiders maintain a significant holding in Guangdong Taienkang Pharmaceutical Co., Ltd.. Insiders own CN¥2.6b worth of shares in the CN¥6.1b company. This may suggest that the founders still own a lot of shares. You can click here to see if they have been buying or selling.

我们的信息显示,内部人士在广东太恩康药品有限公司持有大量股份。内部人士拥有价值26亿人民币的股份,而该公司的市值为61亿人民币。这可能表明创始人仍然持有很多股份。您可以点击这里查看他们是否有买入或卖出。

General Public Ownership

公众持股

The general public-- including retail investors -- own 45% stake in the company, and hence can't easily be ignored. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

公众,包括散户投资者,持有该公司45%的股份,因此无法轻易被忽视。尽管这种持股比例相当可观,但如果决策与其他大股东不一致,这可能不足以改变公司政策。

Next Steps:

下一步:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Consider risks, for instance. Every company has them, and we've spotted 2 warning signs for Guangdong Taienkang Pharmaceutical you should know about.

我发现了解谁拥有一家公司非常有趣。然而,要真正获得洞察,我们还需要考虑其他信息。例如,考虑风险。每家公司都有风险,而我们发现了关于广东泰恩康药品的两个警告信号,你应该知道。

If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.

如果你像我一样,你可能想考虑这家公司是会增长还是缩小。幸运的是,你可以查看这份免费的报告,了解分析师对其未来的预测。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注意:本文中的数字是根据过去十二个月的数据计算得出的,指的是截至财务报表日期的月份最后一天的12个月期间。这可能与完整年度的年报数字不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对本文有反馈?对内容有疑虑?请直接与我们联系。或者,发送电子邮件至 editorial-team (at) simplywallst.com。
这篇来自Simply Wall St的文章是一般性的。我们根据历史数据和分析师预测提供评论,采用无偏见的方法,我们的文章并不旨在提供财务建议。它不构成对任何股票的买入或卖出建议,也未考虑到您的目标或财务状况。我们旨在为您提供以基本数据驱动的长期分析。请注意,我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St在提到的任何股票中均没有持仓。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发